Active Ingredient History

  • Now
Imagabalin was an investigational drug that acted as a ligand for the α2δ subunit of the voltage-dependent calcium channel, with some selectivity for the α2δ1 subunit over α2δ2. It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.   Wikipedia

  • SMILES: CCC[C@@H](C)C[C@H](N)CC(=O)O
  • Mol. Mass: 173.26
  • ALogP: 1.61
  • ChEMBL Molecule:
More Chemistry
imagabalin | pd 0332334 | pd-0332334 | pf-00195889


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue